T2005010
Triflusal impurity B
European Pharmacopoeia (EP) Reference Standard
Sinônimo(s):
2-Hydroxy-4-(trifluoromethyl)benzoic acid, 4-(Trifluoromethyl)salicylic acid
Faça loginpara ver os preços organizacionais e de contrato
About This Item
Produtos recomendados
grau
pharmaceutical primary standard
família API
triflusal
fabricante/nome comercial
EDQM
aplicação(ões)
pharmaceutical (small molecule)
formato
neat
temperatura de armazenamento
2-8°C
InChI
1S/C8H5F3O3/c9-8(10,11)4-1-2-5(7(13)14)6(12)3-4/h1-3,12H,(H,13,14)
chave InChI
XMLFPUBZFSJWCN-UHFFFAOYSA-N
Descrição geral
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Aplicação
Triflusal impurity B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Embalagem
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Outras notas
Sales restrictions may apply.
Escolha uma das versões mais recentes:
Certificados de análise (COA)
Lamentamos, não temos COA para este produto disponíveis online no momento.
Se precisar de ajuda, entre em contato Atendimento ao cliente
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Journal of pharmaceutical and biomedical analysis, 46(3), 456-462 (2007-12-21)
This study describes the development and evaluation of an analytical method for the characterization of triflusal (2-acetoxy-4-(trifluoromethyl) benzoic acid) dispersed in sustained delivery systems prepared using supercritical fluid impregnation technology. Characterization assays comprised the determination of the percentage of triflusal
Naunyn-Schmiedeberg's archives of pharmacology, 371(1), 81-88 (2004-12-17)
Triflusal is a fluorinated derivative of acetylsalicylic acid (ASA) with demonstrated antithrombotic activity. Recently, evidence for a neuroprotective effect has been obtained. The aim of this study was to compare the neuroprotective effects of the main metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic
Archives internationales de pharmacodynamie et de therapie, 284(1), 155-165 (1986-11-01)
The effect of triflusal, acetylsalicylic acid (ASA), and of their principal metabolites 2-hydroxy-4-trifluoromethylbenzoic acid (HTB) and salicylic acid (SA), alone or combined with dypiridamole (DIP) and/or PGE1 on cyclic AMP levels in washed rat platelets (37 degrees C, 4 min)
The Journal of pharmacy and pharmacology, 44(11), 935-937 (1992-11-01)
2-Hydroxy-4-trifluoromethylbenzoic acid (HTB) is the main active metabolite of triflusal, an antiplatelet drug. The in-vitro binding of HTB to human serum was studied in the presence of different drugs. The results indicate that no statistically significant changes are observed in
European journal of drug metabolism and pharmacokinetics, 16(4), 269-273 (1991-10-01)
The pharmacokinetic profile of triflusal (2-acetoxy-4-trifluoromethyl benzoic acid) and its main metabolite HTB (2-hydroxy-4-trifluoromethyl benzoic acid) has been studied in 8 healthy subjects (4 males and 4 females), after a single oral dose of 900 mg of triflusal. Plasma concentrations
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica